US stocks open flat after Trump raises global tariffs to 15%
US equities were little changed on Monday after President Donald Trump announced an increase in global tariffs to 15%, following a Supreme Court
Business
Business
Almirall profit quadruples in 2025 as dermatology fuels growth push
Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of €46.2 million, which was 357% more than its 2024
Investing
NZD/USD forecast ahead of FOMC minutes, RBNZ interest rate decision
The NZD/USD exchange rate continued its strong rally last week, reaching its highest level since June last year. It has now soared in
Investing
USD/ZAR forecast as the South African rand rally gains steam
The South African rand remains in a bull market as the country’s economic recovery gains steam. The USD/ZAR pair dropped to 15.92 on
Investing
AUD/USD forecast: golden cross forms ahead of FOMC minutes
The Australian dollar pulled back slightly on Tuesday after the Reserve Bank of Australia (RBA) released minutes of its last monetary policy meeting
Investing
USD/JPY forecast: Yen targets 150 as chips drive Japan exports higher
The Japanese yen wavered on Wednesday as investors reacted to the ongoing bearish bets on the US dollar, soaring Japanese exports, and wait
Investing
USD/INR forecast: Rupee outlook as Indian bond yields jump
The USD/INR exchange rate continued its recovery this year, moving from a low of 83.77 in May last year to the current 91.
Economy
ETH eyes further dip as Buterin looks to sell more holdings
The cryptocurrency market opened the new weekly candle bearish, as Bitcoin, Ether, and XRP tested key support levels. Ether, the second-largest cryptocurrency by
Economy
Citrini research: S&P 500 to drop 38% from 2026 highs by June 2028
In a sweeping and provocative macro-analysis titled “The 2028 Global Intelligence Crisis,” Citrini Research has outlined a sobering vision of a financial future
Economy
Why is Arcellx stock up 80% today? Gilead’s $7.8B answer
Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a